SYDNEY, AUSTRALIA - JANUARY 13: Ozempic is medicine for adults with type 2 diabetes . Wegovy is ... [+] prescribed for long-term weight loss in adults and children. Both contain the active ingredient semaglutide, on January 13, 2025, in Sydney, Australia (Photo by Steve Christo - Corbis/Corbis via Getty Images)Corbis via Getty ImagesThe stock price of Hims & Hers Health (NYSE: HIMS), a telehealth platform, has surged an impressive 43% over the past week. A major driver of this growth was the company's widel ...

Company Overview - Hims & Hers Health, Inc. (HIMS) shares increased by 27.7% in the last trading session, closing at $59.18, with a notable trading volume compared to typical sessions [1] - The stock has experienced a significant 66.3% gain over the past four weeks, reaching a new all-time high following a successful Super Bowl advertisement [1] Earnings Expectations - The company is projected to report quarterly earnings of $0.12 per share, reflecting a year-over-year increase of 1100% [2] - Expected revenues for the upcoming report are $471.42 million, which is a 91.2% increase from the same quarter last year [2] Stock Performance Insights - The consensus EPS estimate for Hims & Hers Health has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [3] - The stock currently holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook [3] Industry Context - Hims & Hers Health operates within the Zacks Medical Info Systems industry, which includes other companies like Nyxoah SA (NYXH) [3] - Nyxoah's consensus EPS estimate for its upcoming report is -$0.48, representing a 17.1% decline from the previous year, and it also holds a Zacks Rank of 3 (Hold) [4]

Big pharma tried to stop Hims & Hers' Super Bowl ad.Hims & Hers (HIMS 1.51%) launched a Super Bowl ad this week, and everyone from pharmaceutical companies to pharmacists tried to block it. Travis Hoium explains why that's a great sign that the company's disruptive potential is real.*Stock prices used were end-of-day prices of Feb. 11, 2025. The video was published on Feb. 12, 2025. ...

Much of this owes to the 350% gains in the stock in the past year alone, which followed subscriber andMy articles are written with a mind to owning a stock for years, not trying to predict price movements in a few months. I don't do target prices; I do valuations.I first entered investing in 2020 as an individual value investor, keen to understand the fundamentals of businesses and buy their shares at attractive prices. From May 2022 to May 2023, I worked as an investment advisory representative at Fidelity ...

Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The decliners were Novo Nordisk (NVO -2.90%), famously the company behind Wegovy, and Viking Therapeutics (VKTX -7.34%), which is far along in its development of an advanced GLP-1-based obesity treatment. The gainer was Hims & Hers Healthcare (HIMS 5.22%).On the day, the latter company's share price rose by over 5%, while Novo Nordisk's slid by almost 3%, and Viking took a more than 7% tumble.A ...

Core Insights - Hims & Hers Health has transformed into a healthcare platform focusing on personalized and affordable solutions through a telehealth model, indicating strong growth potential in the healthcare sector [1] Company Overview - The company is positioned to become a household name due to its innovative approach and financial performance [1] Industry Context - The emphasis on telehealth solutions reflects a broader trend in the healthcare industry towards digital and remote care, which is increasingly being adopted by consumers [1]

The New York Stock Exchange with a Hims & Hers Health banner is pictured in the Manhattan borough of New York City.Hims & Hers is facing scrutiny from lawmakers over what they claim is a "misleading" advertisement for its weight loss offerings that's slated to run during the Super Bowl on Sunday.Sens. Dick Durbin (D-Ill.) and Roger Marshall (R-Kan.) wrote a letter to the U.S. Food and Drug Administration on Friday expressing concerns over an "upcoming advertisement" that "risks misleading patients by omitti ...

Group 1: Impact of Tariffs on MedTech Sector - President Trump's executive order imposes a 25% tariff on goods from Canada and Mexico, and a 10% tariff on Chinese imports, significantly affecting the U.S. healthcare sector reliant on these countries for medical devices and pharmaceuticals [4][5][6] - The tariffs are expected to drive up production costs for medical technology companies, which may lead to higher prices for healthcare providers and patients, potentially resulting in fewer patient visits and delayed medical treatments [2][5][6] - Goldman Sachs estimates that a five-percentage-point increase in U.S. tariff rates could reduce S&P 500 earnings per share by 1% to 2%, with a potential overall reduction of 2% to 3% in forecasts if the tariffs are implemented [7] Group 2: Resilient MedTech Companies - ResMed is well-positioned due to its manufacturing facilities in multiple countries, including the U.S., and is expected to see a 21.9% earnings growth on an 8.9% revenue increase in fiscal 2025 [10][11] - Hims & Hers, with minimal reliance on affected countries, targets a $360 million U.S. total addressable market and anticipates 600% growth in 2024 earnings driven by a 68.2% revenue surge [12][13] - Medtronic's exposure to imports from China is less than 1% of total revenues, indicating limited direct impact from tariffs, and it is expected to report 4.8% earnings growth on 3.7% revenue growth in fiscal 2025 [14][15]

Hims & Hers Health, Inc.’s (HIMS) investors have been experiencing some short-term gains from the stock of late. Shares of the San Francisco, CA-based health and wellness platform have surged 69.2% in the past three months, outperforming the industry’s 14.5% gain. In the same time frame, the stock outperformed the sector and S&P 500’s 3.7% decline and 6.5% growth, respectively.Two major developments of HIMS in recent months include the announcement of its third-quarter 2024 results and the announcement that ...

Stock Performance - Hims & Hers Health, Inc closed at $31 86, up 1 01% from the previous session, outperforming the S&P 500 which lost 0 47%, the Dow which dropped 0 31%, and the Nasdaq which decreased by 0 51% [1] - The stock has risen 30 44% over the past month, leading the Medical sector's gain of 3 2% and the S&P 500's gain of 1 67% [1] Earnings and Revenue Forecast - The company is forecasted to report an EPS of $0 12, a 1100% increase from the same quarter last year [2] - Revenue is expected to be $471 42 million, a 91 15% increase compared to the same quarter of the previous year [2] Analyst Estimates and Zacks Rank - Recent changes in analyst estimates reflect near-term business trends, with positive revisions indicating confidence in the company's performance [3] - The Zacks Rank system, which integrates estimate changes, has a strong track record, with 1 ranked stocks averaging a 25% annual return since 1988 [5] - Hims & Hers Health, Inc currently holds a Zacks Rank of 3 (Hold) [5] Valuation and Industry Rank - The company is trading at a Forward P/E ratio of 60 16, higher than the industry average of 35 99, indicating a premium valuation [6] - The Medical Info Systems industry, part of the Medical sector, has a Zacks Industry Rank of 44, placing it in the top 18% of all industries [6] - The top 50% of industries by Zacks Industry Rank outperform the bottom half by a factor of 2 to 1 [7]